A compound represented by Formula (I): or a pharmaceutically acceptable salt or tautomer thereof, wherein: X is O, OH, or Cl; L is -(CH 2 ) m Y(CH 2 ) p -; Y is O, N or S(O) q ; R 1 is C 6 -C 10 aryl or heteroaryl, wherein the aryl and heteroaryl are substituted with R a and R b , and optionally substituted with one or more R e ; one of R a and R b is hydrogen and the other is -(CH 2 ) r CO 2 R x , -OCH 2 CO 2 R x , -(CH 2 ) r tetrazole, -(CH 2 ) r Oxadiazolone, -(CH 2 ) r tetrazolone, -(CH 2 ) r thiadiazolol, -(CH2)r isoxazol-3-ol, -(CH 2 ) r P(O)(OH)OR x , -(CH 2 ) r S(O) 2 OH, -(CH 2 ) r C(O)NHCN, or -(CH 2 ) r C(O)NHS(O) 2 alkyl; R c is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, halogen, -CN, -OR x , -CO 2 R x , or NO 2 ; R d is methyl, cyclohexyl, pyridinyl, thiazolyl, phenyl or thienyl, wherein each cyclohexyl, pyridinyl, thiazolyl, phenyl or thienyl is optionally substituted with one or more substituents independently selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, -OH, CN, and amino; each R x is independently at each occurrence hydrogen or C 1 -C 6 alkyl; each R e is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, -OR y , C 1 -C 6 haloalkyl, -NHR z , -OH, or -CN; R f is H or absent; each R y and R z is independently hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl; m is 0, 1 or 2; p is 1 or 2, wherein m + p < 3; q is 0, 1, or 2; r is 0 or 1; and the dotted line is an optional double bond; with the proviso that R c is not -CN when X is O, L is -SCH 2 - and R d is optionally substituted phenyl; and that R c is not C 1 -C 6 alkyl when X is O, L is -SCH 2 - and R d is methyl. X is O, OH, or Cl; L is -(CH 2 ) m Y(CH 2 ) p -; Y is O, N or S(O) q ; R 1 is C 6 -C 10 aryl or heteroaryl, wherein the aryl and heteroaryl are substituted with R a and R b , and optionally substituted with one or more R e ; one of R a and R b is hydrogen and the other is -(CH 2 ) r CO 2 R x , -OCH 2 CO 2 R x , -(CH 2 ) r tetrazole, -(CH 2 ) r Oxadiazolone, -(CH 2 ) r tetrazolone, -(CH 2 ) r thiadiazolol, -(CH2)r isoxazol-3-ol, -(CH 2 ) r P(O)(OH)OR x , -(CH 2 ) r S(O) 2 OH, -(CH 2 ) r C(O)NHCN, or -(CH 2 ) r C(O)NHS(O) 2 alkyl; R c is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, halogen, -CN, -OR x , -CO 2 R x , or NO 2 ; R d is methyl, cyclohexyl, pyridinyl, thiazolyl, phenyl or thienyl, wherein each cyclohexyl, pyridinyl, thiazolyl, phenyl or thienyl is optionally substituted with one or more substituents independently selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, -OH, CN, and amino; each R x is independently at each occurrence hydrogen or C 1 -C 6 alkyl; each R e is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, -OR y , C 1 -C 6 haloalkyl, -NHR z , -OH, or -CN; R f is H or absent; each R y and R z is independently hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl; m is 0, 1 or 2; p is 1 or 2, wherein m + p < 3; q is 0, 1, or 2; r is 0 or 1; and the dotted line is an optional double bond; with the proviso that R c is not -CN when X is O, L is -SCH 2 - and R d is optionally substituted phenyl; and that R c is not C 1 -C 6 alkyl when X is O, L is -SCH 2 - and R d is methyl. <EOS>